Aptinyx Inc

Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EVANSTON, Ill.,--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies evaluating NYX-783, a novel NMDA receptor positive allosteric modulator, in models of post-traumatic stress disorder (PTSD) were published in the journal, Molecular Psychiatry. The publication, entitled "Positive modulation of N-methyl-D-aspartate r

Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783

Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.

Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

Aptinyx Inc (NASDAQ: APTX) shares are plunging after results from a Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN).  NYX-2925 did not achieve statistically significant separation from placebo on the study's primary endpoint, which.

Aptinyx Shares Tank On Disappointed Data From Mid-Stage Diabetic Peripheral Neuropathy Study

Shares of Aptinyx Inc. APTX, -4.49% tumbled 48.7% in premarket trading on Thursday after the company said an experimental treatment for painful diabetic peripheral neuropathy failed to meet the primary endpoint in a Phase 2b clinical trial. "The data from this study do not currently point to a path forward in development for painful DPN," Aptinyx CEO Andy Kidd said in a news release.

Aptinyx's stock falls 48% after drug fails in Phase 2b trial

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN). NYX-2925 did not achieve statistically significant separation from placebo on the study's primary endpoint, which assessed the change from baseline

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

Alnylam Pharmaceuticals

Bristol-Myers

Blueprint Medicines

Coherus BioSciences

Hutchison China MediTech Ltd.

Tarsus Pharmaceuticals

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.

7 Biotech Stocks to Buy With Key Catalysts for April

Aptinyx, Inc. (APTX) CEO Andy Kidd on Q4 2021 Results - Earnings Call Transcript

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2021 and provided updates across the company's pipeline of novel NMDA receptor modulators. “We continued our strong execution against an ambitious set of clinical development goals in 2021, reaching several key milestones during th

Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights

Here is how Aptinyx Inc. (APTX) and Doximity (DOCS) have performed compared to their sector so far this year.

Has Aptinyx Inc. (APTX) Outpaced Other Medical Stocks This Year?

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200-6205 (domestic) or

Aptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022

Here is how Aptinyx Inc. (APTX) and ICU Medical (ICUI) have performed compared to their sector so far this year.

Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in the Neuropsychiatry Panel discussion at the 42nd Annual Cowen Health Care Conference at 9:10 a.m. EST on Monday, March 7, 2022. A live webcast of the panel discussion will be available to view on the “E

Aptinyx to Participate in the 42nd Annual Cowen Health Care Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment of 305 patients in the company's ongoing Phase 2b study of NYX-2925 in fibromyalgia. Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety follow-up period. The company expects to report results from the stud

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will host a virtual portfolio review event today beginning at 10:00 a.m. ET. Presented in a live webcast format, the company will discuss its approach to the development of novel NMDA receptor modulators and review its pipeline of four clinical development programs, with particular focus on NYX-2925

Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET. A live webcast of the fireside chat will be available to view on the

Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), comprising leading researchers and physicians in the areas of neuropsychiatry, neurology, and chronic pain. The SAB will work closely with the Aptinyx management team to provide scientific and clinical input into the investigation,

Aptinyx Announces Formation of Scientific Advisory Board

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today provided a corporate update and highlighted development milestones anticipated in 2022. “Following a year of extraordinary execution, Aptinyx enters 2022 positioned for transformational growth, with a robust slate of Phase 2 study readouts fast approaching,” said Andy Kidd, M.D., president and

Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual portfolio review event on Wednesday, February 9, 2022 from 10:00 a.m. to 11:30 a.m. ET. The live webcast event will review Aptinyx's full pipeline of clinical development programs, with particular focus on NYX-2925, the company's drug candidate in developme

Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD). The Phase 2b study is designed to be well-positioned for consideration as registration-supportive, taking into account guidance received in a Type C meeting wi

Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 13, 2022 at 12:00 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco, California. A l

Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference

Investors need to pay close attention to Aptinyx (APTX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Aptinyx (APTX) Stock?

The stock price of Aptinyx Inc (NASDAQ: APTX) increased by over 9% during intraday trading today. This is why it happened.

Aptinyx Stock (APTX): Why The Price Increased Today

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held November 29, 2021 through December 2, 2021. The pre-recorded fireside chat will be available to view on the “Events and Presentations” page in the “Inv

Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

Aptinyx, Inc. (APTX) CEO Norbert Riedel on Q3 2021 Results - Earnings Call Transcript

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2021 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor modulators. “The coming year promises to be an exciting time for Aptinyx as we approach several major development milestones across each

News for Aptinyx Inc Stock (APTX)